This trial is evaluating whether Treatment will improve 2 primary outcomes, 12 secondary outcomes, and 2 other outcomes in patients with Cancer of Pancreas. Measurement will happen over the course of At various post-infusion time points assessed up to 22 weeks.
This trial requires 69 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
Findings from a recent study confirmed the value of radical surgery in pancreatic cancer; however, in a large proportion of patients adjuvant therapy has to be considered. Chemotherapy remained a therapeutic option. New developments in imaging and radiotherapy warrant further clarification.
We could not find any benefit of surgical resection and adjuvant chemotherapy in terms of overall or local long-term survival rate. The authors conclude that surgical resection alone is not advisable to be used for the treatment of cancer of the pancreas.
The main risk factors of pancreas cancer are smoking, alcohol consumption, obesity, and diabetes. Most of pancreas cancers develop from chronic pancreatic diseases or from benign tumors in the pancreas. Alcohol consumption has an adverse impact on the natural history and prognosis of the disease.
Pancreatic cancer is the tenth most common cancer worldwide, with an annual incidence of over 25,000 cases, and is a disease where survival depends on an early diagnosis. A high occurrence of pancreatic neuroendocrine neoplasms and a poorer prognosis justifies a more detailed epidemiological screening for such neoplasms.
At a population level in the US of people diagnosed with cancer of pancreas there are more women than men. The proportion of patients diagnosed with cancer in pancreas has decreased between the years of 1990-2004, with the exception of patients diagnosed in 2009-2014, but the trends are similar among other conditions. The percentage of pancreas cancer in females has remained around 90% for all diagnoses and for all age groups, with the exception of patients aged 70-79. Pancreas cancer and C-cell carcinoma remain the two most common types of cancer reported.
Signs of pancreatic cancer include a sudden sharp, intense, high-pitched pain or burning in the upper part of the back, flank, chest and/or abdomen. The pain appears to be steady or in quick succession. The pain is often dull or achy although sometimes sudden, severe, and sometimes stabbing or stabbing and throbbing. These signs are referred from the pancreas and often lead to the discovery of an obstructing obstruction. The obstruction causes increased pressure (bodily) or air (vascular) within the pancreatic cavity. Signs of obstructive jaundice or bleeding may be present. There may also be changes in appetite.
There are many different clinical trials available for cancer of pancreas. It is difficult to select which to enter. We consider the following points before entering a clinical trial (1) type of treatment being studied, (2) type of chemotherapy administered, (3) whether it will be adjuvant or neoadjuvant, (4) the expected benefit to the patients, (5) cost, and (6) the likelihood of survival benefit.
Pancreatic cancer is a rare disease and has a poor overall survival rate. The mean survival rate was 14.2 months since its diagnosis in the past 4 years. In spite of such low survival rate, some patients with pancreatic cancer benefited from surgical treatment. Although curative resection is the only possible treatment for pancreatic cancer, some patients might also survive if they can get a radical resection with complete disease removal. To improve the survival rate of patients with curative resection, adjuvant treatment should be investigated.
Only 5% of the reported trials on pancreatic cancer in the last 5 years have been in the first line treatment. Combining CT with chemotherapy is used more frequently as compared with CT alone. It seems that our field of knowledge of pancreatic cancer and treatment is moving very fast. At the moment, it is not possible to predict the outcome of the treatment with high accuracy.
The main cause of pancreatic cancer is chronic pancreatitis (66%) followed by pancreatic ductal adenocarcinoma (23%). Both conditions need to be well managed to treat them.
The most recent studies have shown that [cytotoxic drugs] can be extremely effective in treating pancreatic cancer and they are the best tolerated by patients. Additionally, they are highly effective and can provide a survival time benefit to patients that would otherwise have been denied otherwise based on the disease itself in this era of chemotherapy. However, [antibiotic drugs] are still considered first line of treatment and are being used for treatment of this disease and can work to inhibit bacterial infection.
The treatment of [pancreatic cancer](https://www.withpower.com/clinical-trials/pancreatic-cancer) depends on age and the type of tumor that grows; it varies enormously depending on the stage of diagnosis; and the results of clinical trials are often controversial. The use of pancreatic cancer therapy is only suggested or discouraged by the National Comprehensive Cancer Network. Because there are few randomized trials with long-term follow-ups, there are many questions that need to be more fully explored. New approaches, new technologies, and new combinations of medicines have the highest potential to improve the management of patients with pancreatic cancer.